Article
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Blood advances - 23 Jan 2024
Cai Sheng F, Huang Ying, Lance Jennie R, Mao Hsiaoyin Charlene, Dunbar Andrew J, McNulty Samantha N, Druley Todd, Li Yan, Baer Maria R, Stock Wendy, Kovacsovics Tibor, Blum William G, Schiller Gary J, Olin Rebecca L, Foran James M, Litzow Mark, Lin Tara, Patel Prapti, Foster Matthew C, Boyiadzis Michael, Collins Robert H, Chervin Jordan, Shoben Abigail, Vergilio Jo-Anne, Heerema Nyla A, Rosenberg Leonard, Chen Timothy L, Yocum Ashley O, Druggan Franchesca, Marcus Sonja, Stefanos Mona, Druker Brian J, Mims Alice S, Borate Uma, Burd Amy, Byrd John C, Levine Ross L, Stein Eytan M
Abstract excerpt
ABSTRACT: Enasidenib (ENA) is an inhibitor of isocitrate dehydrogenase 2 (IDH2) approved for the treatment of patients with IDH2-mutant relapsed/refractory acute myeloid leukemia (AML). In this phase 2/1b Beat AML substudy, we applied a risk-adapted approach to assess the efficacy of ENA monotherapy for patients aged ≥60 years with newly diagnosed IDH2-mutant AML in whom genomic profiling demonstrated that mutant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.